BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Our Partners
BIND and Pfizer have entered into a global collaboration agreement to develop and commercialize ACCURINS® utilizing select small-molecule targeted therapies. The collaboration aims to employ BIND's MEDICINAL NANOENGINEERING® platform to impart tissue and cellular targeting capabilities to molecularly targeted drugs.
BIND and AstraZeneca have entered into a strategic collaboration to develop and commercialize an Accurin based on AstraZeneca's prodrug Barasertib (AZD1152) with optimal critical nanoparticle properties such that a short infusion has the potential for extended target cover from increased biodistribution to the tumor site. Barasertib is a potent selective inhibitor of the Aurora B kinase that successfully completed randomized Phase 2 studies in elderly AML patients unfit for chemotherapy. BIND's collaboration with AstraZeneca has resulted in the Aurora B Kinase inhibitor Accurin AZD2811, which became the second Accurin candidate to enter clinical development. Accurin AZD2811 offers the potential to overcome the therapeutic index challenges which previously limited the clinical development of agents in the aurora B kinase inhibitor class in hematological and solid tumors.
BIND and Roche have entered into a research agreement to discover novel nanomedicines. This collaboration will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands to create ACCURINS® for the treatment of diseases in a number of therapeutic areas outside of oncology.
BIND and Merck have entered into a joint research and development agreement to discover and develop novel nanomedicines to treat cancer. The goal of this collaboration is to leverage BIND’s proprietary nanomedicine technology to create targeted ACCURINS® with enhanced therapeutic properties based on novel, potent payloads from Merck’s preclinical oncology portfolio.
BIND and Macrophage Therapeutics, a subsidiary of Navidea Biopharmaceuticals, Inc., have entered into a research collaboration to engineer ACCURINS® with the Manocept™ targeting platform that enables selective, efficient binding to CD206 positive disease-associated macrophages. Upon achievement of proof-of-concept, the companies anticipate expanding the collaboration to develop Manocept-linked ACCURINS® as a novel, potent approach to impact the tumor microenvironment which, in many forms of cancer, is a barrier to immune effector cells.
BIND and Synergy Pharmaceuticals have entered into a a research collaboration to engineer ACCURINS® incorporating Synergy’s proprietary uroguanylin analogs to explore the potential targeting of guanylate cyclase-C (GC-C) receptors expressed on tumors, specifically GI malignancies. Upon achievement of proof-of-concept, the companies anticipate expanding the collaboration to enhance the potential effect of uroguanylin-based ACCURINS® by incorporating therapeutic payloads.
BIND and Amgen established the first major partnership focused on developing a novel and targeted kinase inhibitor nanomedicine. Kinase inhibitor ACCURINS® have the potential to more effectively treat cancer with optimized therapeutic properties by simultaneously targeting the tumor environment, specific tumor cells, and specific molecular pathways within the cells. This collaboration was completed in the second quarter of 2014.
Partnership Inquiries
Direct partnership inquiries to:
Dan Koerwer
Chief Business Officer